Morten Henneveld appointed interim CEO of Atlas Antibodies

The Board of Atlas Antibodies and Dan Pitulia have mutually agreed that Dan will leave his position as the CEO of the Atlas Antibodies Group.
 

Morten Henneveld has assumed the role of interim CEO as of November 1, 2026. Morten was most recently CEO of OssDsign and prior to that held leadership positions at GN Group, Zimmer Biomet and Coloplast.
 

“We thank Dan for his leadership, and we look forward to partnering with Morten and the team as we embark on the next chapter together. His extensive leadership experience and track record of driving strategic change will be instrumental in the company’s continued development”, says Åsa Riisberg, Chair of Atlas Antibodies.
 

“We are pleased to welcome Morten to Atlas Antibodies and look forward to working with him. We thank Dan for his valuable contributions”, says Thomas Kidane, Co-Head of Patricia Industries.